|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment strategies for advanced hepatocellular carcinoma:Sorafenib vs hepatic arterial infusion chemotherapy显示文摘Sorafenib is used worldwide as a first-line standardsystemic agent for advanced hepatocellular carcinoma(HCC) on the basis of the results of two large-scale Phase Ⅲ trials. Conversely,hepatic arterial infusion chemotherapy(HAIC) is one of the most recommended treatments in Japan. Although there have been no randomized controlled trials comparing sorafenib with HAIC,several retrospective analyses have shown no significant differences in survival between the two therapies. Outcomes are favorable for HCC patients exhibiting macroscopic vascular invasion when treated with HAIC rather than sorafenib,whereas in HCC patients exhibiting extrahepatic spread or resistance to transcatheter arterial chemoembolization,good outcomes are achieved by treatment with sorafenib rather than HAIC. Additionally,sorafenib is generally used to treat patients with Child-Pugh A,while HAIC is indicated for those with either Child-Pugh A or B. Based on these findings,we reviewed treatment strategies for advanced HCC. We propose that sorafenib might be used as a first-line treatment for advanced HCC patients without macroscopic vascular invasion or Child-Pugh A,while HAIC is recommended for those with macroscopic vascular invasion or Child-Pugh A or B. Additional research is required to determine the best second-line treatment for HAIC non-responders with Child-Pugh B through future clinical trials. | Issei Saeki Takahiro Yamasaki Masaki Maeda Takuro Hisanaga Takuya Iwamoto Koichi Fujisawa Toshihiko Matsumoto Isao Hidaka Yoshio Marumoto Tsuyoshi Ishikawa Naoki Yamamoto Yutaka Suehiro Taro Takami Isao Sakaida | 2018 | World Journal of Hepatology2018，10，9： | 10 |
| 2 | Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma显示文摘AIM To evaluate the inhibitory effects of deferasirox(DFX) against hepatocellular carcinoma(HCC) through basic and clinical studies.METHODS In the basic study, the effect of DFX was investigated in three hepatoma cell lines(Hep G2, Hep3 B, and Huh7), as well as in an N-nitrosodiethylamine-induced murine HCC model. In the clinical study, six advanced HCC patients refractory to chemotherapy were enrolled. The initial dose of DFX was 10 mg/kg per day and was increased by 10 mg/kg per day every week, until the maximum dose of 30 mg/kg per day. The duration of a single course of DFX therapy was 28 consecutive days. In the event of dose-limiting toxicity(according to the Common Terminology Criteria for Adverse Events v.4.0), DFX dose was reduced.RESULTS Administration of DFX inhibited the proliferation of hepatoma cell lines and induced the activation of caspase-3 in a dose-dependent manner in vitro. In the murine model, DFX treatment significantly suppressed the development of liver tumors(P < 0.01), and significantly upregulated the mR NA expression levels of hepcidin(P < 0.05), transferrin receptor 1(P < 0.05), and hypoxia inducible factor-1α(P < 0.05) in both tumor and non-tumor tissues, compared with control mice. In the clinical study, anorexia and elevated serum creatinine were observed in four and all six patients, respectively. However, reduction in DFX dose led to decrease in serum creatinine levels in all patients. After the first course of DFX, one patient discontinued the therapy. We assessed the tumor response in the remaining five patients; one patient exhibited stable disease, while four patients exhibited progressive disease. The one-year survival rate of the six patients was 17%.CONCLUSION We demonstrated that DFX inhibited HCC in the basic study, but not in the clinical study due to dose-limiting toxicities. | Issei Saeki Naoki Yamamoto Takahiro Yamasaki Taro Takami Masaki Maeda Koichi Fujisawa Takuya Iwamoto Toshihiko Matsumoto Isao Hidaka Tsuyoshi Ishikawa Koichi Uchida Kenji Tani Isao Sakaida | 2016 | World Journal of Gastroenterology2016，22，40： | 3 |
| 3 | Bone-marrow-derived cells cultured in serum-free medium reduce liver fibrosis and improve liver function in carbon-tetrachloride-treated cirrhotic mice显示文摘 | Takuya Iwamoto Shuji Terai Takuro Hisanaga Taro Takami Naoki Yamamoto Shoko Watanabe Isao Sakaida | 2013 | Cell and Tissue Research2013，，3： | 2 |
| 4 | Extramedullary Hematopoiesis Generates Ly-6Chigh Monocytes That Infiltrate Atherosclerotic Lesions显示文摘 | Clinton S. Robbins Aleksey Chudnovskiy Philipp J. Rauch Jose-Luiz Figueiredo Yoshiko Iwamoto Rostic Gorbatov Martin Etzrodt Georg F. Weber Takuya Ueno Nico van Rooijen Mary Jo Mulligan-Kehoe Peter Libby Matthias Nahrendorf Mikael J. Pittet Ralph Weisslede | 2012 | Circulation2012，，2： | 2 |
| 5 | Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension显示文摘 | Tsuyoshi Ishikawa Shogo Shiratsuki Takashi Matsuda Takuya Iwamoto Taro Takami Koichi Uchida Shuji Terai Takahiro Yamasaki Isao Sakaida | 2014 | Journal of Gastroenterology2014，，9： | 1 |
| 6 | Angiotensin-Converting Enzyme Inhibition Prevents the Release of Monocytes From Their Splenic Reservoir in Mice With Myocardial Infarction显示文摘 | Florian Leuschner Peter Panizzi Isabel Chico-Calero Won Woo Lee Takuya Ueno Virna Cortez-Retamozo Peter Waterman Rostic Gorbatov Brett Marinelli Yoshiko Iwamoto Aleksey Chudnovskiy Jose-Luiz Figueiredo David E. Sosnovik Mikael J. Pittet Filip K. Swirski R | 2010 | Circulation Research2010，，： | 1 |
| 7 | Splenectomy enhances the anti-fibrotic effect of bone marrow cell infusion and improves liver function in cirrhotic mice and patients显示文摘 | Takuya Iwamoto Shuji Terai Yuko Mizunaga Naoki Yamamoto Kaoru Omori Koichi Uchida Takahiro Yamasaki Yasuhiko Fujii Hiroshi Nishina Isao Sakaida | 2012 | Journal of Gastroenterology2012，，3： | 1 |
| 8 | Angiotensin-Converting Enzyme Inhibition Prevents the Release of Monocytes From Their Splenic Reservoir in Mice With Myocardial Infarction显示文摘 | Florian Leuschner Peter Panizzi Isabel Chico-Calero Won Woo Lee Takuya Ueno Virna Cortez-Retamozo Peter Waterman Rostic Gorbatov Brett Marinelli Yoshiko Iwamoto Aleksey Chudnovskiy Jose-Luiz Figueiredo David E. Sosnovik Mikael J. Pittet Filip K. Swirski R | 2010 | Circulation Research2010，，11： | 1 |
| 9 | Excitatory and inhibitory 5-hydroxytryptamine (5-HT) receptors expressed in the isolated porcine uterine muscles显示文摘 | Tatsuro Nakamura Takio Kitazawa Jinshan Cao Takuya Iwamoto Hiroki Teraoka Koichi Kadota Tetsuro Taneike | 2008 | European Journal of Pharmacology2008，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员